CO6561779A2 - Anticuerpos anti-il 10- humanizados para el tratamiento de lupus sistémico eritematoso (sle) - Google Patents

Anticuerpos anti-il 10- humanizados para el tratamiento de lupus sistémico eritematoso (sle)

Info

Publication number
CO6561779A2
CO6561779A2 CO12109341A CO12109341A CO6561779A2 CO 6561779 A2 CO6561779 A2 CO 6561779A2 CO 12109341 A CO12109341 A CO 12109341A CO 12109341 A CO12109341 A CO 12109341A CO 6561779 A2 CO6561779 A2 CO 6561779A2
Authority
CO
Colombia
Prior art keywords
treatment
erythemate
sle
humanized antibodies
system lupus
Prior art date
Application number
CO12109341A
Other languages
English (en)
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Rottgen
Benjamin Daelken
Andre Engling
Chantal Zuber
Niklas Czeloth
Demand Andrea Wartenberg
Marcus Gutscher
Kranz Judith Wessls
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of CO6561779A2 publication Critical patent/CO6561779A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo humanizado o quimérico o su fragmento, capaz de ligar a interleucina-lO (IL-10), y el uso de este anticuerpo o su fragmento en el tratamiento de condiciones médicas mediadas por un nivel o actividad elevados de IL-10.
CO12109341A 2009-11-30 2012-06-29 Anticuerpos anti-il 10- humanizados para el tratamiento de lupus sistémico eritematoso (sle) CO6561779A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
CO6561779A2 true CO6561779A2 (es) 2012-11-15

Family

ID=43798505

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12109341A CO6561779A2 (es) 2009-11-30 2012-06-29 Anticuerpos anti-il 10- humanizados para el tratamiento de lupus sistémico eritematoso (sle)

Country Status (17)

Country Link
US (4) US8956607B2 (es)
EP (2) EP2470209B1 (es)
JP (2) JP2013511994A (es)
KR (2) KR101802261B1 (es)
CN (2) CN102811736B (es)
AU (2) AU2010323037B2 (es)
BR (2) BR112012012912A2 (es)
CA (2) CA2782007C (es)
CO (1) CO6561779A2 (es)
CR (2) CR20120359A (es)
IL (2) IL219954A (es)
MX (2) MX350206B (es)
NZ (2) NZ600899A (es)
RU (2) RU2587622C2 (es)
SG (2) SG10201407936XA (es)
WO (2) WO2011064398A1 (es)
ZA (1) ZA201204843B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350206B (es) 2009-11-30 2017-08-28 Biotest Ag Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2014257123A1 (en) * 2013-04-24 2015-10-15 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3105251A4 (en) * 2014-02-10 2017-11-15 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
CN107430123B (zh) * 2014-11-28 2020-04-14 通用电气健康护理生物科学股份公司 用于在传感器表面上检测分析物-配体结合的方法
AU2015367684A1 (en) * 2014-12-15 2017-07-06 Galapagos Nv Antibodies for IL-17C
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
WO2017093947A1 (en) 2015-12-04 2017-06-08 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
KR20230110304A (ko) 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
CA3213824A1 (en) * 2021-03-23 2022-09-29 Organogenesis, Inc. Methods, kits, and compositions for characterizing an anti-inflammatory response of a product

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MX9200161A (es) * 1991-01-16 1992-07-01 Schering Corp Uso de interleucina-10 en inmunoterapia adoptiva de cancer
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
EP0600970B1 (en) 1991-08-06 1999-12-08 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
SI2289936T1 (sl) * 2002-12-16 2017-10-30 Genentech, Inc. Imunoglobulinske variante in njihove uporabe
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
UA117446C2 (uk) * 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
MX350206B (es) * 2009-11-30 2017-08-28 Biotest Ag Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).

Also Published As

Publication number Publication date
RU2581812C2 (ru) 2016-04-20
CA2782007C (en) 2018-07-24
JP6005519B2 (ja) 2016-10-12
MX2012006197A (es) 2012-06-19
CN102811736A (zh) 2012-12-05
US8956607B2 (en) 2015-02-17
US9605066B2 (en) 2017-03-28
WO2011064398A1 (en) 2011-06-03
CN102711829A (zh) 2012-10-03
EP2470209A1 (en) 2012-07-04
SG10201407935YA (en) 2015-01-29
EP2470208A1 (en) 2012-07-04
SG10201407936XA (en) 2015-01-29
CR20120358A (es) 2013-01-23
CA2782004A1 (en) 2011-06-03
RU2587622C2 (ru) 2016-06-20
AU2010323036A1 (en) 2012-07-19
US20150064179A1 (en) 2015-03-05
US20120321618A1 (en) 2012-12-20
AU2010323037B2 (en) 2015-01-29
AU2010323036B2 (en) 2015-01-29
IL219955A0 (en) 2012-07-31
KR101802261B1 (ko) 2017-11-28
ZA201204843B (en) 2020-02-26
NZ600899A (en) 2014-09-26
KR101802260B1 (ko) 2017-11-28
KR20120115289A (ko) 2012-10-17
CN102711829B (zh) 2016-03-16
IL219954A (en) 2016-10-31
MX2012006198A (es) 2012-06-19
CN102811736B (zh) 2016-01-20
MX350206B (es) 2017-08-28
KR20120103664A (ko) 2012-09-19
RU2012127381A (ru) 2014-01-10
CA2782007A1 (en) 2011-06-03
US20150218270A1 (en) 2015-08-06
CR20120359A (es) 2013-01-25
US8852871B2 (en) 2014-10-07
IL219954A0 (en) 2012-07-31
NZ600894A (en) 2014-09-26
AU2010323037A1 (en) 2012-07-19
IL219955A (en) 2016-08-31
WO2011064399A1 (en) 2011-06-03
JP2013511994A (ja) 2013-04-11
MX343228B (es) 2016-10-26
BR112012012912A2 (pt) 2016-10-25
EP2470209B1 (en) 2020-01-01
RU2012127380A (ru) 2014-01-10
BR112012012917A2 (pt) 2016-10-25
US9540436B2 (en) 2017-01-10
JP2013511995A (ja) 2013-04-11
US20120321617A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
CO6561779A2 (es) Anticuerpos anti-il 10- humanizados para el tratamiento de lupus sistémico eritematoso (sle)
CY1122278T1 (el) Αντι il-36r αντισωματα
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
EA201270769A1 (ru) Антитела к cgrp
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
TN2012000567A1 (en) Glucagon analogues
CL2013001213A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de este para tratar artritis reumatoide.
EP3702372A3 (en) Anti-cd40 human antibodies
CA2953714C (en) Anti-tnfa antibodies with ph-dependent antigen binding
IL232219B (en) Human or humanized antibodies against tar-dna-binding protein 43kda and their uses
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
MY162791A (en) Anti-il-23 antibodies
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
MY177564A (en) Anti-nr10 antibody and use thereof
PH12016501366A1 (en) Novel anti-baff antibodies
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX2013013832A (es) Proteínas de unión receptoras fc.
MX2014000531A (es) Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
PH12017500722A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MY154715A (en) Anti-nr10 antibody and use thereof
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.

Legal Events

Date Code Title Description
FG Application granted